Programme Introduction
About this programme
🩺 Medical CME
✅ Case-Based Learning
📊 Guideline-Aligned
Leukaemias and lymphomas are among the most common childhood malignancies, and outcomes have improved substantially as treatment has shifted toward risk-stratified regimens and targeted agents rather than uniform chemotherapy protocols.
Paediatric acute lymphoblastic leukaemia, acute myeloid leukaemia, and paediatric lymphomas each carry distinct biology, risk stratification systems, and treatment pathways that oncology teams must apply precisely to optimise outcomes while minimising long-term toxicity.
TerraLeap’s Paediatric Leukaemias & Lymphomas programme brings oncology teams up to date on contemporary treatment regimens, including BTK and BCL-2 inhibitors, through case-based learning grounded in real clinical scenarios.
The programme covers diagnostic classification, risk stratification, first-line and relapsed/refractory treatment approaches, and the emerging role of targeted therapies in paediatric haematological malignancy.
Guideline-aligned reasoning — built through real clinical case discussion.
Programme Scope
What this programme covers
This programme covers the diagnosis, risk stratification, and contemporary treatment of paediatric leukaemias and lymphomas.
🧬
Diagnostic classification
Distinguishing acute lymphoblastic leukaemia, acute myeloid leukaemia, and lymphoma subtypes in children.
📊
Risk stratification
Applying current risk-group criteria to guide treatment intensity.
💊
Contemporary regimens
First-line chemotherapy protocols and their evolution in paediatric oncology.
🎯
Targeted therapies
The role of BTK and BCL-2 inhibitors in relapsed or high-risk disease.
🔁
Relapsed/refractory management
Treatment approaches when first-line therapy is insufficient.
🩺
Case-based learning
Real clinical scenarios illustrating diagnostic and treatment decision-making.
⚖️
Balancing efficacy and toxicity
Minimising long-term treatment-related complications in paediatric patients.
Learning Objectives
What you will achieve
After completing this programme, learners will be able to apply current diagnostic, risk-stratification, and treatment approaches to paediatric leukaemias and lymphomas.
Each objective reflects a stage in the contemporary paediatric haemato-oncology care pathway.
01
Classify paediatric leukaemias and lymphomas using current diagnostic and biological criteria
02
Apply risk-stratification systems to guide treatment intensity decisions
03
Describe the role of BTK and BCL-2 inhibitors in contemporary treatment regimens
04
Evaluate treatment options for relapsed or refractory paediatric haematological malignancy
05
Apply case-based reasoning to real-world paediatric oncology scenarios
06
Balance treatment efficacy against long-term toxicity considerations in children
07
Stay current with evolving paediatric leukaemia and lymphoma treatment protocols
Target Audience
Who can enroll
This programme is designed for oncology professionals involved in the diagnosis and treatment of paediatric leukaemias and lymphomas.
Whether managing newly diagnosed or relapsed cases, this programme strengthens decision-making across contemporary paediatric haemato-oncology care.
🩺
Paediatric oncologists and haematologists managing leukaemia and lymphoma cases
🏥
Oncology nurses and allied health professionals in paediatric cancer units
👩⚕️
Trainees in paediatric haematology-oncology building foundational knowledge
🎯
Clinicians seeking an update on targeted-therapy treatment options
📊
Multidisciplinary teams involved in paediatric oncology case discussions
Programme Certification
Your certificate
Upon successful completion of this programme, you will receive a digital certificate recognising your achievement and the competencies you have acquired throughout the course.
Certificates for TerraLeap programmes are issued and signed by authorised TerraLeap representatives. For programmes delivered in collaboration with universities, institutions, or industry organisations, certificates are jointly issued and co-signed by authorised representatives of both TerraLeap and the respective partner.
Each certificate carries a unique Certificate ID and QR code to enable instant authenticity verification — making it easy to share with employers, licensing bodies, or professional networks as evidence of your learning.
Note on scope. TerraLeap certificates confirm successful completion of the respective programme and recognise your professional development and continuing education. They do not constitute a professional licence or regulatory authorisation unless explicitly stated in the programme description.
TERRALEAP
Certificate ID
TL-2026-AB7K3X9P
Official
Seal
Certificate of Completion
Successfully Completed
Awarded in recognition of academic achievement
This is to certify that
XXXXX
has successfully completed the prescribed course of study, demonstrating commitment, diligence, and proficiency in
Pediatric Leukemias and Lymphomas
and is hereby awarded this certificate by TerraLeap, recognising the candidate's mastery of the syllabus and successful evaluation.